Peptide News Digest

Health Canada Clears Foundayo, Hims and Noom Start Selling Compounded Peptides, Roche Starts ZYNERGY Trial

Canada authorizes the Foundayo pill, Hims and Noom launch compounded peptides, and a Mayo study finds no clear GLP-1 survival gain in endometrial cancer.

10 stories · Covering regulatory, industry, clinical-trials, research

Editor's Note

Two telehealth companies started selling compounded peptides this week, weeks after HHS said it would not enforce compounding rules for six unapproved peptides. Hims & Hers opened Peptides+ with sermorelin and four other unapproved products, and its chief medical officer told CNBC the company doesn't have the data it is used to having. Noom's new OpenRx brand sells sermorelin, NAD+, and oxytocin tablets. Hims plans to add BPC-157 and TB-500, and Noom says it is reviewing them. A planned sports medicine program from Dr. James Andrews's foundation and Vector Science could produce some of the controlled human data these products lack, though it has not named a peptide or a trial yet. A Mayo Clinic analysis carries a related warning about records studies. GLP-1 users with endometrial cancer looked much better off when compared the way earlier studies did, but the difference was no longer significant when follow-up started at diagnosis. On the drug side, Health Canada authorized Lilly's Foundayo pill, Roche began a 480-person trial pairing petrelintide with enicepatide, and Pakistani clinics found a lower-cost semaglutide performed like Novo's over a year.

Health Canada Authorizes Lilly's Foundayo Pill for Weight Management and Type 2 Diabetes, With Pharmacy Supply Expected in January

Health Canada authorized Foundayo (orforglipron) on November 13 for adults with obesity and for overweight adults with at least one weight-related condition such as high blood pressure or sleep apnea, as well as for type 2 diabetes, The Canadian Press reported. A Lilly spokesperson said the company expects the daily pills in pharmacies in January. Novo Nordisk's Wegovy pill is still awaiting Health Canada approval, and endocrinologist Dr. Ehud Ur said he is waiting for trial results on whether orforglipron protects the heart, as semaglutide and tirzepatide do.

CNBC: Hims & Hers Launches Peptides+ With Five Unapproved Compounded Treatments, Including Sermorelin and Glutathione

Hims & Hers launched Peptides+ on November 18 with compounded sermorelin, glutathione, NAD+, vitamin B12, and L-carnitine, none of them FDA-approved, CNBC reported. More than 10,000 people joined its early access list within 15 days, according to a company spokesperson, and Hims plans to add BPC-157 and TB-500 later without giving a date. Chief medical officer Dr. Anant Vinjamoori said, "We don't have all of this data that we're used to having with compounds like this." For now, patients with serious heart, liver, or kidney disease are not eligible.

Noom Launches OpenRx, Selling Compounded Sermorelin, NAD+, and Oxytocin Tablets and Reviewing BPC-157 and TB-500

Noom launched OpenRx on November 17 as a separate brand for clinician-prescribed peptide and preventive treatments, filled through its 503A compounding pharmacy network. It starts with injectable sermorelin and NAD+, a dissolvable tablet that combines PT-141, oxytocin, and tadalafil for sexual health, and an oxytocin-only tablet. Chief medical officer Dr. Jeffrey Egler said the company is reviewing BPC-157 and TB-500. The release promises "transparent pricing" but lists no prices.

Roche Starts ZYNERGY, a 480-Person Phase 2 Trial Pairing Zealand's Amylin Drug Petrelintide With Enicepatide

Zealand Pharma said Roche has started ZYNERGY, a randomized, double-blind Phase 2 dose-finding trial that will enroll about 480 adults with obesity, or with overweight and at least one weight-related condition. Participants will receive weekly petrelintide, an amylin analog, together with enicepatide, Roche's GLP-1/GIP dual agonist, at one of three dose regimens, or placebo, or either drug alone. The main goal is percent weight change at week 40, and the results will guide doses for Phase 3.

Dr. James Andrews's Foundation and Vector Science Plan Clinical Programs for Peptides in Sports Injuries and Osteoarthritis

The Andrews Research & Education Foundation in Gulf Breeze, Florida, and Vector Science and Therapeutics of Mequon, Wisconsin, which is chaired by former HHS Secretary Tommy Thompson, said they will design and start clinical programs testing Vector's pharmaceutical-grade peptides for soft-tissue repair, muscle regeneration in aging athletes, and degenerative osteoarthritis. The release does not name the peptides, a trial start date, or funding, and it says the peptides may be investigational for these uses. The partners also plan peptide courses for sports medicine fellows and residents.

Dignify Therapeutics Doses the First Volunteer With DTI-117, an On-Demand Peptide Meant to Trigger Bowel Emptying

Dignify Therapeutics of Research Triangle Park, North Carolina, dosed the first healthy volunteer on November 17 in a randomized, placebo-controlled Phase 1 study of DTI-117, a short-acting peptide that activates the NK2 receptor. The study will give single intramuscular doses to up to 40 people across up to five dose groups to test safety and how the body handles the drug. The NIH is funding the trial, and Dignify expects early results in early 2027. The company is developing DTI-117 for people with neurogenic bowel dysfunction, a condition that can leave them dependent on caregivers to empty their bowels.

Mayo Clinic-Led Records Study: GLP-1 Use Was Not Clearly Tied to Longer Survival in Endometrial Cancer

In TriNetX records of women aged 18 to 75 diagnosed with endometrial cancer from 2018 to 2024, five-year survival was 91.6% for 2,646 women with a GLP-1 drug record in the year before diagnosis and 90.2% for matched non-users (hazard ratio 0.81, 95% CI 0.65 to 1.02, not statistically significant). Comparing users with women who never took a GLP-1, the method used in some earlier studies, produced a hazard ratio of 0.58. Writing in Gynecologic Oncology, the authors say survival benefits reported in other cancers should be treated with caution until prospective trials finish.

Islamabad Clinics' Records: Lower-Cost Biosimilar Semaglutide Matched Novo's Version on Blood Sugar Over 52 Weeks

In records of 1,000 adults with type 2 diabetes who started weekly biosimilar or brand-name (innovator) semaglutide at two diabetes centers in Islamabad, Pakistan, HbA1c fell 1.42 and 1.39 percentage points after 52 weeks, a difference within the preset equivalence margin. Weight fell 6.3% and 6.2%, and 93.2% and 94.6% were still on treatment at one year. The study was observational, not randomized, and the authors, writing in Diabetology, call for prospective studies that also check immune reactions to the copies.

Heidelberg Lab Study: The Pain Neuropeptide Alpha-CGRP Blunted Cartilage Cells' Response to Healthy Loading

Heidelberg University researchers grew cartilage from human joint cells, treated it with alpha-calcitonin gene-related peptide (alpha-CGRP) for 24 hours, and then compressed it in a pattern that normally builds cartilage. The peptide did not change how the cells sensed pressure, but it blocked the usual rise in proteoglycan production, and blocking WNT signaling prevented that effect. Writing in Aging Cell, the team says alpha-CGRP may be a target in osteoarthritis. The work was done in lab-grown tissue only.

Lithuanian Mouse Study: Semaglutide Caused More Weight Loss Than Matched Calorie Cuts but No Extra Muscle Weakness

In obese 8-month-old male mice given the same food intake for 28 days, those on daily semaglutide injections lost 20.9% of body mass versus 14.8% for mice on calorie restriction alone, Lithuanian Sports University researchers report in the Journal of Cachexia, Sarcopenia and Muscle. Both groups lost a similar amount of soleus muscle, and muscle force per unit of mass did not differ. The semaglutide mice ran farther on a treadmill, which the authors mostly attribute to their lower body weight.